Busilvex

busulfan

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Busilvex. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Busilvex.

What is Busilvex?

Busilvex is a concentrate to be made up into a solution for infusion (drip into a vein). It contains the active substance busulfan.

What is Busilvex used for?

Busilvex is used in adults and children as a ‘conditioning’ (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells). This type of transplant is used in patients who need to replace their blood-making cells, because they have a blood disorder (such as a rare type of anaemia) or a cancer of the blood. Busilvex treatment is followed by treatment with another medicine (cyclophosphamide in adults, and cyclophosphamide or melphalan in children).

The medicine can only be obtained with a prescription.

How is Busilvex used?

Busilvex should be used by a doctor who has experience in treatments given before transplantation. 

The recommended dose of Busilvex in adults is 0.8 mg per kilogram body weight. In children up to 17 years of age, the recommended dose of Busilvex is based on the weight of the child and varies between 0.8 and 1.2 mg/kg. Busilvex is given as a central intravenous infusion (drip into a central vein in the chest). Each infusion lasts for two hours and it is given to the patient every six hours on four consecutive days before treatment with cyclophosphamide or melphalan and the transplant. 

Before receiving Busilvex, patients are given anticonvulsive medicines (to prevent seizures) and anti-emetic medicines (to prevent vomiting).

How does Busilvex work?

The active substance in Busilvex, busulfan, belongs to a group of medicines called ‘alkylating agents’. These substances are ‘cytotoxic’. This means that they kill cells, especially cells that develop rapidly, such as cancer or progenitor (or ‘stem’) cells (cells that make other types of cell). 

Busulfan is used before transplantation to destroy abnormal cells and the patient’s existing haematopoietic progenitor cells. This is called ‘myeloablation’. Cyclophosphamide or melphalan is then used to suppress the immune system, so that the body’s natural defences are decreased. This helps the transplanted cells to ‘engraft’ (when they start to grow and produce normal blood cells).

How has Busilvex been studied?

Busilvex has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells. There were two main studies involving 103 adults and one involving 55 children. The main measures of effectiveness were the number of patients with myeloablation (with reduced counts of white blood cells and platelets) and ‘engraftment’ (the time for the white blood cells to return to higher levels).

What benefit has Busilvex shown during the studies?

All adults and children achieved myeloablation. On average, engraftment was reached in 10 days in adults and 11 days in children with ‘autotransplantation’ (when the patient receives their own cells, harvested and stored before the transplant). Engraftment was obtained in 13 days in adults and 21 days in children with ‘allotransplantation’ (when the patient receives cells from a donor).

What is the risk associated with Busilvex?

Apart from the decrease in blood cell counts, which is the intended effect of the medicine, the most serious side effects of Busilvex are infection, liver disorders including blocking of a liver vein, graft versus host disease (when the transplanted cells attack the body) and respiratory (lung) disorders. For the full list of all side effects reported with Busilvex, see the package leaflet.

Busilvex must not be used in people who are hypersensitive (allergic) to busulfan or any of the other ingredients. It must not be used in women who are pregnant. Breast-feeding should be stopped when treatment with Busilvex is started. Busilvex can affect fertility in both sexes. Because of this, female patients should not become pregnant during treatment and for up to six months afterwards, and male patients are advised not to father a child during and for up to six months after treatment with Busilvex.

Why has Busilvex been approved?

The CHMP concluded that the effectiveness of Busilvex had been shown, and that it provides an alternative to busulfan tablets, which have disadvantages such as the large number of tablets that need to be taken. The Committee decided that Busilvex’s benefits are greater than its risks as conditioning treatment prior to haematopoietic progenitor cell transplantation. The Committee recommended that Busilvex be given marketing authorisation.

Other information about Busilvex

The European Commission granted a marketing authorisation valid throughout the EU for Busilvex on 9 July 2003.

For more information about treatment with Busilvex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Busilvex : EPAR - Summary for the public BG = bălgarski 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public ES = español 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public CS = čeština 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public DA = dansk 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public DE = Deutsch 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public ET = eesti keel 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public EL = elliniká 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public EN = English 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public FR = français 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public IT = italiano 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public LV = latviešu valoda 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public LT = lietuvių kalba 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public HU = magyar 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public MT = Malti 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public NL = Nederlands 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public PL = polski 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public PT = português 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public RO = română 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public SK = slovenčina 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public SL = slovenščina 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public FI = suomi 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public SV = svenska 19/09/2008 27/02/2014
Busilvex : EPAR - Summary for the public HR = Hrvatski 19/09/2008 27/02/2014

This EPAR was last updated on 25/06/2014 .

Authorisation details

Product details

Product details for Busilvex
NameBusilvex
Agency product numberEMEA/H/C/000472
Active substance

busulfan

International non-proprietary name (INN) or common name

busulfan

Therapeutic area Hematopoietic Stem Cell Transplantation
Anatomical therapeutic chemical (ATC) code L01AB01

Publication details

Publication details for Busilvex
Marketing-authorisation holder

Pierre Fabre Médicament

Revision14
Date of issue of marketing authorisation valid throughout the European Union09/07/2003

Contact address:

Pierre Fabre Médicament
45, place Abel Gance
92654 Boulogne Billancourt Cedex
France

Product information

Product information

23/05/2014  Busilvex -EMEA/H/C/000472 -PSUSA/0464

Name Language First published Last updated
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014
Busilvex : EPAR - Product Information HR = Hrvatski 19/09/2008 25/06/2014

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012
Busilvex : EPAR - All Authorised presentations HR = Hrvatski 04/02/2008 22/08/2012

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.

Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic-progenitor-cell transplantation in paediatric patients.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Busilvex : EPAR - Procedural steps taken before authorisation HR = Hrvatski 21/10/2005  
Busilvex : EPAR - Scientific Discussion HR = Hrvatski 21/10/2005  

Authorised

This medicine is approved for use in the European Union

News

Related information

More information on Busilvex

This product is no longer an orphan medicine. It was originally designated an orphan medicine on 29 December 2001. Busilvex was withdrawn from the Community register of orphan medicinal products in July 2013 at the end of the 10-year period of market exclusivity